Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise September 6, 2023 San Francisco Biotechnology Network News News, Syndication Comments Off on Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise The Boston biotech has sold two experimental drugs — a liver disease medicine and a TYK2 inhibitor — to Gilead and Takeda respectively. Click here to view original post